A simple way to enhance Doxil® therapy: Drug release from liposomes at the tumor site by amphiphilic block copolymer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The antitumor efficacy of Doxil® is hindered by the poor release of the active drug from the liposome at the tumor sites. This study investigates a possibility to enhance drug release from the liposomes and increase therapeutic efficacy of Doxil® by administering Pluronic block copolymers once the liposomal drug accumulates in the tumor sites. In our study, the fluorescence de-quenching experiments were designed to investigate the drug release from liposome by Pluronic P85. MTT cytotoxicity assay and confocal microscopy images were carried out to determine whether Pluronic P85 could facilitate release of Dox from Doxil®. Anti-tumor growth and distribution of drug were evaluated when Pluronic P85 was injected 1 hr, 48 hrs, or 96 hrs after the Doxil® administration in A2780 human ovarian cancer xenografts. Addition of Pluronic P85 resulted in release of Dox from the liposomes accompanied with significant increases of Dox delivery and cytotoxic effect in cancer cells. The greatest anti-tumor effect of single injection of Doxil® was achieved when Pluronic P85 was administered 48 hrs after Doxil®. The Confocal tile scanning images of tumor section showed that copolymer treatment induced the release of the drug in the tumors from the vessels regions to the bulk of the tumor. No release of the drug remaining in circulation was observed. Our study has demonstrated a simple approach for localized release of Dox from liposome by Pluronic P85 at the tumor site, which was therapeutically beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 4×
“Barenholz [20] supports the notion that the free Dox is released in the tumor interstitial fluid and this provides for the anticancer effect of Doxil®.”
BackgroundInfluentialKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“The latter produce viscoelastic gel-like extracellular matrix (ECM) that is rich in fibronectin and collagen, and is associated with poor survival [9, 10].”
BackgroundMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474
Self-citationBatrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278 · cited 1×
“Similarly to a mixture of L61 and F127 employed in SP1049C P85 has shown ability to sensitize MDR cancer cells [38].”
BackgroundSelf-citationDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 3×
“Thus, methods that are able to improve the permeability of the matrix, for example collagen synthesis inhibitor s [11], collagenase and hyaluronidase [12], or tumor-penetrating peptides [13] have been used to facilitate the distribution and enhance the efficacy of liposomal drugs [14].”
BackgroundMethodDelivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · cited 1×
“This drug has shown considerable activity and favorable safety profile in clinical trials [39, 40].”
Background
Cited by
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Poloxamer: A versatile tri-block copolymer for biomedical applications
Zarrintaj, P., Ramsey, J. D., Samadi, A., Atoufi, Z., Yazdi, M. K., Ganjali, M. R., Amirabad, L. M., Zangene, E., Farokhi, M., Formela, K., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.04.028 · Cited by 404
Yang, Y., Sun, B., Zuo, S., Li, X., Zhou, S., Li, L., Luo, C., Liu, H., Cheng, M., Wang, Y., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1725 · Cited by 307
Pande, S. (2023) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2023.2247036 · Cited by 258
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Self-citation
Metadata
- Authors
- Zhao, Y., Alakhova, D. Y., Kim, J. O., Bronich, T. K., & Kabanov, A. V.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 168
- Issue
- 1
- Pages
- 61-69
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2049298366
- Cited by
- 125
- References
- 14
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A simple way to enhance Doxil® therapy: Drug release from liposomes at the tumor site by amphiphilic block copolymer. https://app.cochat.ai/papers/10.1016/j.jconrel.2013.02.026
- The paper
- Zhao, Y., Alakhova, D. Y., Kim, J. O., Bronich, T. K., & Kabanov, A. V. (2013). A simple way to enhance Doxil® therapy: Drug release from liposomes at the tumor site by amphiphilic block copolymer. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2013.02.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.